ERBB2 and neoplasm: Previous reports state that not all patients have an equal response to NAC and that this response may vary depending on biological characteristics of the tumour and their immunohistochemistry-based molecular subtype, In basal-like tumours achieving a complete pathological response (pCR) rate in 45% (95%CI: 24–68), HER2+ in 45% (95%CI: 23–68), and Luminal A in 6% (95%CI:1–21) [6].